A peptide vaccine targeting Kras, when combined with Avasimibe, facilitated CD8+ T-cell tumour infiltration, IFN-γ expression and decreased the presence of regulatory T-cells in the TME and improved control of tumours in a lung cancer mouse model [165]. The gene discussed is KRAS; the disease is neoplasm.